The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease
Open accessAbstract
BACKGROUND: A majority of mutations within the beta-amyloid region of the amyloid precursor protein (APP) gene cause inherited forms of intracerebral hemorrhage. Most of these mutations may also cause cognitive impairment, but the Arctic APP mutation is the only known intra-beta-amyloid mutation to date causing the more typical clinical picture of Alzheimer disease. OBJECTIVE: To describe features of 1 Swedish and 1 American family with the previously reported Arctic APP mutation. DESIGN, SETTING, AND PARTICIPANTS: Affected and nonaffected carriers of the Arctic APP mutation from the Swedish and American families were investigated clinically. In addition, 1 brain from each family was investigated neuropathologically. RESULTS: The clinical picture, with age at disease onset in the sixth to seventh decade of life and dysfunction in multiple cognitive areas, is indicative of Alzheimer disease and similar to the phenotype for other Alzheimer disease APP mutations. Several affected mutation carriers displayed general brain atrophy and reduced blood flow of the parietal lobe as demonstrated by magnetic resonance imaging and single-photon emission computed tomography. One Swedish case and 1 American case with the Arctic APP mutation came to autopsy, and both showed no signs of hemorrhage but revealed severe congophilic angiopathy, region-specific neurofibrillary tangle pathological findings, and abundant amyloid plaques. Intriguingly, most plaques from both of these cases had a characteristic ringlike character. CONCLUSIONS: Overall, our findings corroborate that the Arctic APP mutation causes a clinical and neuropathological picture compatible with Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, 228 PSEN1 mutations have been identified causing ADAD (49, 303, 304, 440, 566, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [49]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APP mutations can lead to cerebrovascular pathology including BBB breakdown and cerebral amyloid angiopathy (CAA), as shown in humans (49, 211, 356, 674) and transgenic animal models expressing human APP mutations (56, 57, 137, 321, 322, 331, 336, 405, 420, 464, 467, 512, 513, 579, 606).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with 'vasculotropic' APP mutations within A 𝛃 21-23 residues including Dutch (E693Q), Arctic (E693G), Flemish (A692G), Iowa (D694N), and Italian (E693K) mutation (49, 211, 335, 356, 526, 674) develop prominent CAA (238, 640) causing extensive cerebrovascular pathology.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“CBF reductions have also been reported in humans carrying vasculotropic APP mutations (49).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
(1995) · Cited by 2,809
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513
Self-citationBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I. M., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,399
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [20]Wechsler D. Wechsler Adult Intelligence Scale – Revised: Manual. New York: Psychological Corporation; 1981. [Google Scholar]
- [21]Lezak M. Neuropsychological Assessment. 3rd. New York: Oxford University Press; 1995. [Google Scholar]
Cited by
Sorted by citations
Items 101–115 of 115
Hvoslef‐Eide, M. (2012) · ORCA Online Research @Cardiff (Cardiff University)
Characterisation of transgenic mouse models of Alzheimer's disease
Graham, L. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Castellani, R. J., Lee, H., Petersen, R. B., Zhu, X., & Perry, G. L. (2011) · Therapy · doi:10.2217/thy.11.62
Functional imaging of Alzheimer's disease
Taler, V., & Saykin, A. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.025
Cummings, J. L. (2021) · touchREVIEWS in Neurology · doi:10.17925/usn.2021.17.2.70
Goldman, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7482-2_7
IMPACTS OF HYPERTENSION AND THROMBOSIS IN A RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY (rTg-DI)
Stanisavljevic, A. (2022) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-stanisavljevic-aleksandra-2022
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00023-1
Li, C., Zhang, X., Xia, J., Liu, S., Du, Y., Li, S., Zhang, S., Zhang, Y., Ji, F., Jiao, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202515584
Angiopathie amyloïde cérébrale héréditaire
Grangeon, L., Nicolas, G., & Wallon, D. (2026) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(26)49255-6
Mao, A., Ruiz‐Riquelme, A., Barghash, M. M., Silver, N. R. G., Lau, H. H. C., Stuart, E., Zampar, S., Sehlin, D., Syvänen, S., Pollanen, M. S., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02390-z
Self-citationDistinct amyloid-β filament fold in individuals with APP Flemish mutation
Khaki, P. S. S., Guillen-Poza, P. A., Wong, C., Kan, C., Sharma, R., Sugimura, R., Robinson, A., Valbuena, A., Ng, R. C.-L., Yang, Y., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01855-y
Metadata
- Authors
- Basun, H., Bogdanovic, N., Ingelsson, M., Almkvist, O., Näslund, J., Axelman, K., Bird, T. D., Nochlin, D., Schellenberg, G. D., Wahlund, L.-O., & Lannfelt, L.
- Affiliations
- Karolinska Institutet (SE)
- Uppsala University (SE)
- Stockholm University (SE)
- University of Washington (US)
- ORCID
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-04-01
- Volume
- 65
- Issue
- 4
- Pages
- 499
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC2723757
- OpenAlex
- W2126866809
- Cited by
- 115
- References
- 26
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 7 · 2016: 3 · 2015: 4 · 2014: 10 · 2013: 6 · 2012: 10
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (P50AG005136)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- amyloid precursor protein, early-onset Alzheimer's disease, familial Alzheimer's disease, intracerebral hemorrhage, cognitive impairment, brain atrophy, cerebral amyloid angiopathy, neurofibrillary tangles, amyloid plaques, neuropathology
- MeSH terms
- Age Factors, Aged, Alzheimer Disease, Atrophy, Brain, Child, Electroencephalography, Female, Genotype, Genetic Carrier Screening, Humans, Magnetic Resonance Imaging, Middle Aged, Neurologic Examination, Neuropsychological Tests, Parietal Lobe, Pedigree, Phenotype, Receptors, Cell Surface, Regional Blood Flow, Sweden, United States, Tomography, Emission-Computed, Single-Photon, Amyloid beta-Protein Precursor, Age of Onset, Plaque, Amyloid, Protease Nexins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
